<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01612884</url>
  </required_header>
  <id_info>
    <org_study_id>1106005745</org_study_id>
    <nct_id>NCT01612884</nct_id>
  </id_info>
  <brief_title>Antiplatelet Therapy Guided by Thrombelastography in Patients With Acute Coronary Syndromes (TEGCOR Study)</brief_title>
  <official_title>Antiplatelet Therapy Guided by Thrombelastography in Patients With Acute Coronary Syndromes (TEGCOR Study)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Indiana University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Indiana University</source>
  <brief_summary>
    <textblock>
      Personalized treatment approaches and antiplatelet drug choice have been proposed to optimize
      safety of coronary stenting by reducing heart attacks and repeat interventions while
      simultaneously minimizing adverse bleeding events. This study compares the efficacy of two
      laboratory guided treatment algorithms to personalize antiplatelet medication choice after
      coronary stenting
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Slow enrollment
  </why_stopped>
  <start_date>August 2011</start_date>
  <completion_date type="Actual">March 2017</completion_date>
  <primary_completion_date type="Actual">March 2017</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Thrombelastography (TEG) MA</measure>
    <time_frame>1 day</time_frame>
    <description>Persistence of high tensile clot strength measured by TEG 16-24 hours after reloading of either clopidogrel or prasugrel</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Ischemic Events</measure>
    <time_frame>6 months</time_frame>
    <description>Death, recurrent myocardial infarction, recurrent unstable angina, repeat coronary intervention</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Bleeding Events</measure>
    <time_frame>6 months</time_frame>
    <description>Major or Minor Bleeding according to TIMI criteria</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">67</enrollment>
  <condition>Thrombosis</condition>
  <condition>Coronary Artery Disease</condition>
  <arm_group>
    <arm_group_label>TEG</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Clopidogrel non-response defined as MA≥69 Clopidogrel response defined as MA&lt;69</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Light transmittance aggregometry</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Clopidogrel non-response defined as MPA ADP &gt;42.9% Clopidogrel response defined as MPA ADP &lt;42.9%</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Prasugrel</intervention_name>
    <description>Prasugrel 60mg loading dose at time of PCI if clopidogrel non-responder</description>
    <arm_group_label>TEG</arm_group_label>
    <arm_group_label>Light transmittance aggregometry</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Clopidogrel</intervention_name>
    <description>Clopidogrel 300mg loading dose at time of PCI if clopidogrel responder</description>
    <arm_group_label>TEG</arm_group_label>
    <arm_group_label>Light transmittance aggregometry</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients admitted with acute coronary syndrome (unstable angina, non-ST elevation
             myocardial infarction) and referred for coronary angiography.

          -  Current therapy with clopidogrel (at least 300mg loading dose, or 75mg po daily for &gt;5
             days)

          -  Age range 21-75 years.

        Exclusion Criteria:

          -  Unable to give consent

          -  Age younger than 21 years, greater than 75 years

          -  History of stroke

          -  Body weight &lt;60 kg

          -  Acute STEMI,

          -  Thrombocytopenia&lt;100'000,

          -  requirement for chronic warfarin therapy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Eskenazi Health</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Indiana University Health Methodist Hospital</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 4, 2012</study_first_submitted>
  <study_first_submitted_qc>June 4, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 6, 2012</study_first_posted>
  <results_first_submitted>December 29, 2017</results_first_submitted>
  <results_first_submitted_qc>March 28, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">April 26, 2018</results_first_posted>
  <last_update_submitted>March 28, 2018</last_update_submitted>
  <last_update_submitted_qc>March 28, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 26, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Indiana University</investigator_affiliation>
    <investigator_full_name>Rolf Kreutz</investigator_full_name>
    <investigator_title>M.D., Associate Professor of Clinical Medicine</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
    <mesh_term>Thrombosis</mesh_term>
    <mesh_term>Acute Coronary Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Clopidogrel</mesh_term>
    <mesh_term>Ticlopidine</mesh_term>
    <mesh_term>Prasugrel Hydrochloride</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>67 subjects were enrolled and underwent testing on day 0. Only 37 of those subjects underwent PCI, and therefore were randomized to either LTA or TEG guided intervention arm. The remainder of subjects were treated medically without PCI or were referred for CABG (see flow diagram in protocol) and did not get randomized to any intervention arm.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Thrombelastography (TEG) Guided</title>
          <description>Clopidogrel non-response defined as MA≥69 Clopidogrel response defined as MA&lt;69
Prasugrel: Prasugrel 60mg loading dose at time of PCI if clopidogrel non-responder
Clopidogrel: Clopidogrel 300mg loading dose at time of PCI if clopidogrel responder</description>
        </group>
        <group group_id="P2">
          <title>Light Transmittance Aggregometry Guided</title>
          <description>Clopidogrel non-response defined as MPA ADP &gt;42.9% Clopidogrel response defined as MPA ADP &lt;42.9%
Prasugrel: Prasugrel 60mg loading dose at time of PCI if clopidogrel non-responder
Clopidogrel: Clopidogrel 300mg loading dose at time of PCI if clopidogrel responder</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="19"/>
                <participants group_id="P2" count="18"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="19"/>
                <participants group_id="P2" count="18"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Thrombelastography (TEG) Guided</title>
          <description>Clopidogrel non-response defined as MA≥69 Clopidogrel response defined as MA&lt;69
Prasugrel: Prasugrel 60mg loading dose at time of PCI if clopidogrel non-responder
Clopidogrel: Clopidogrel 300mg loading dose at time of PCI if clopidogrel responder</description>
        </group>
        <group group_id="B2">
          <title>Light Transmittance Aggregometry Guided</title>
          <description>Clopidogrel non-response defined as MPA ADP &gt;42.9% Clopidogrel response defined as MPA ADP &lt;42.9%
Prasugrel: Prasugrel 60mg loading dose at time of PCI if clopidogrel non-responder
Clopidogrel: Clopidogrel 300mg loading dose at time of PCI if clopidogrel responder</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="19"/>
            <count group_id="B2" value="18"/>
            <count group_id="B3" value="37"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="55.2" spread="9.8"/>
                    <measurement group_id="B2" value="53.2" spread="10.5"/>
                    <measurement group_id="B3" value="54.2" spread="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="15"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="22"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="15"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                    <measurement group_id="B2" value="18"/>
                    <measurement group_id="B3" value="37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Thrombelastography (TEG) MA</title>
        <description>Persistence of high tensile clot strength measured by TEG 16-24 hours after reloading of either clopidogrel or prasugrel</description>
        <time_frame>1 day</time_frame>
        <population>TEG-MA (mm) at 16-24 hours outcome measure</population>
        <group_list>
          <group group_id="O1">
            <title>Thrombelastography (TEG) Guided</title>
            <description>Clopidogrel non-response defined as MA≥69 Clopidogrel response defined as MA&lt;69
Prasugrel: Prasugrel 60mg loading dose at time of PCI if clopidogrel non-responder
Clopidogrel: Clopidogrel 300mg loading dose at time of PCI if clopidogrel responder</description>
          </group>
          <group group_id="O2">
            <title>Light Transmittance Aggregometry Guided</title>
            <description>Clopidogrel non-response defined as MPA ADP &gt;42.9% Clopidogrel response defined as MPA ADP &lt;42.9%
Prasugrel: Prasugrel 60mg loading dose at time of PCI if clopidogrel non-responder
Clopidogrel: Clopidogrel 300mg loading dose at time of PCI if clopidogrel responder</description>
          </group>
        </group_list>
        <measure>
          <title>Thrombelastography (TEG) MA</title>
          <description>Persistence of high tensile clot strength measured by TEG 16-24 hours after reloading of either clopidogrel or prasugrel</description>
          <population>TEG-MA (mm) at 16-24 hours outcome measure</population>
          <units>mm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
                <count group_id="O2" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="66.4" spread="11"/>
                    <measurement group_id="O2" value="65.8" spread="6.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Student's T-test</non_inferiority_desc>
            <p_value>0.85</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Ischemic Events</title>
        <description>Death, recurrent myocardial infarction, recurrent unstable angina, repeat coronary intervention</description>
        <time_frame>6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Thrombelastography (TEG) Guided</title>
            <description>Clopidogrel non-response defined as MA≥69 Clopidogrel response defined as MA&lt;69
Prasugrel: Prasugrel 60mg loading dose at time of PCI if clopidogrel non-responder
Clopidogrel: Clopidogrel 300mg loading dose at time of PCI if clopidogrel responder</description>
          </group>
          <group group_id="O2">
            <title>Light Transmittance Aggregometry Guided</title>
            <description>Clopidogrel non-response defined as MPA ADP &gt;42.9% Clopidogrel response defined as MPA ADP &lt;42.9%
Prasugrel: Prasugrel 60mg loading dose at time of PCI if clopidogrel non-responder
Clopidogrel: Clopidogrel 300mg loading dose at time of PCI if clopidogrel responder</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Ischemic Events</title>
          <description>Death, recurrent myocardial infarction, recurrent unstable angina, repeat coronary intervention</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
                <count group_id="O2" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Death</title>
              <category_list>
                <category>
                  <title>Event</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>No Event</title>
                  <measurement_list>
                    <measurement group_id="O1" value="19"/>
                    <measurement group_id="O2" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Myocardial Infarction</title>
              <category_list>
                <category>
                  <title>Event</title>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>No Event</title>
                  <measurement_list>
                    <measurement group_id="O1" value="18"/>
                    <measurement group_id="O2" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Recurrent coronary intervention</title>
              <category_list>
                <category>
                  <title>Event</title>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>No Event</title>
                  <measurement_list>
                    <measurement group_id="O1" value="16"/>
                    <measurement group_id="O2" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unstable Angina</title>
              <category_list>
                <category>
                  <title>Event</title>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>No Event</title>
                  <measurement_list>
                    <measurement group_id="O1" value="17"/>
                    <measurement group_id="O2" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Chi-Square</non_inferiority_desc>
            <p_value>0.93</p_value>
            <method>Chi-squared</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Bleeding Events</title>
        <description>Major or Minor Bleeding according to TIMI criteria</description>
        <time_frame>6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Thrombelastography (TEG) Guided</title>
            <description>Clopidogrel non-response defined as MA≥69 Clopidogrel response defined as MA&lt;69
Prasugrel: Prasugrel 60mg loading dose at time of PCI if clopidogrel non-responder
Clopidogrel: Clopidogrel 300mg loading dose at time of PCI if clopidogrel responder</description>
          </group>
          <group group_id="O2">
            <title>Light Transmittance Aggregometry Guided</title>
            <description>Clopidogrel non-response defined as MPA ADP &gt;42.9% Clopidogrel response defined as MPA ADP &lt;42.9%
Prasugrel: Prasugrel 60mg loading dose at time of PCI if clopidogrel non-responder
Clopidogrel: Clopidogrel 300mg loading dose at time of PCI if clopidogrel responder</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Bleeding Events</title>
          <description>Major or Minor Bleeding according to TIMI criteria</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
                <count group_id="O2" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Bleeding</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>No Bleeding</title>
                  <measurement_list>
                    <measurement group_id="O1" value="19"/>
                    <measurement group_id="O2" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Chi-Square</non_inferiority_desc>
            <p_value>&gt;0.05</p_value>
            <method>Chi-squared</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Complete duration of study period (6 months)</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Thrombelastography (TEG) Guided</title>
          <description>Clopidogrel non-response defined as MA≥69 Clopidogrel response defined as MA&lt;69
Prasugrel: Prasugrel 60mg loading dose at time of PCI if clopidogrel non-responder
Clopidogrel: Clopidogrel 300mg loading dose at time of PCI if clopidogrel responder</description>
        </group>
        <group group_id="E2">
          <title>Light Transmittance Aggregometry Guided</title>
          <description>Clopidogrel non-response defined as MPA ADP &gt;42.9% Clopidogrel response defined as MPA ADP &lt;42.9%
Prasugrel: Prasugrel 60mg loading dose at time of PCI if clopidogrel non-responder
Clopidogrel: Clopidogrel 300mg loading dose at time of PCI if clopidogrel responder</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Rolf Kreutz, MD</name_or_title>
      <organization>Indiana University School of Medicine</organization>
      <phone>3179620500</phone>
      <email>rkreutz@iu.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

